CCM
EGRX

Cadence Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cadence Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,490
Closed -$629K – 667
2015
Q3 		$629K Buy
+8,490
New +$706K 0.04% 413

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cadence Capital Management's EGRX Position: Q4 2015 in Review

Cadence Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2015, closing a stake of 8,490 shares — an estimated $629K sold.

Cadence Capital Management first reported a position in EGRX in Q3 2015 and held it in 1 quarter. The position peaked at $629K in Q3 2015. 133 funds tracked by Wall St. Rank hold EGRX as of Q4 2015.

  • Cadence Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Cadence Capital Management sold 8,490 Eagle Pharmaceuticals, Inc. shares in Q4 2015, an estimated $629K.
  • Cadence Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Cadence Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $629K in Q3 2015.
  • 133 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2015.

Based on Cadence Capital Management's 13F filing for Q4 2015, filed 3 Feb 2016.